ATE393170T1 - Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers - Google Patents
Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpersInfo
- Publication number
- ATE393170T1 ATE393170T1 AT02743765T AT02743765T ATE393170T1 AT E393170 T1 ATE393170 T1 AT E393170T1 AT 02743765 T AT02743765 T AT 02743765T AT 02743765 T AT02743765 T AT 02743765T AT E393170 T1 ATE393170 T1 AT E393170T1
- Authority
- AT
- Austria
- Prior art keywords
- antibody
- fragment
- growth factor
- fibroblast growth
- antibody against
- Prior art date
Links
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 title abstract 3
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 4
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001196176 | 2001-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE393170T1 true ATE393170T1 (de) | 2008-05-15 |
Family
ID=19034030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02743765T ATE393170T1 (de) | 2001-06-28 | 2002-06-28 | Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7939077B2 (de) |
| EP (1) | EP1422243B1 (de) |
| JP (1) | JP4152315B2 (de) |
| AT (1) | ATE393170T1 (de) |
| AU (1) | AU2002346127B2 (de) |
| CA (1) | CA2451854A1 (de) |
| DE (1) | DE60226253T2 (de) |
| ES (1) | ES2303859T3 (de) |
| WO (1) | WO2003002608A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241568B2 (en) | 1996-04-03 | 2007-07-10 | Kyowa Hakko Kogyo Co., Ltd. | Anti-fibroblast growth factor-8 monoclonal antibody |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| WO2003057251A1 (fr) * | 2001-12-28 | 2003-07-17 | Kyowa Hakko Kogyo Co., Ltd. | Remedes contre l'arthrite |
| JP2006520610A (ja) * | 2003-03-04 | 2006-09-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ハイブリッド不変領域を産生するのに用いるベクター |
| WO2006121159A1 (ja) * | 2005-05-12 | 2006-11-16 | Kyowa Hakko Kogyo Co., Ltd. | Cd10に特異的に反応するヒト型cdr移植抗体およびその抗体断片 |
| EP2039704A4 (de) | 2006-06-06 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | Monoklonaler antikörper, der dazu fähig ist, sich an den heparinbindenden epidermalen-wachstumsfaktor-ähnlichen wachstumsfaktor zu binden |
| EP2221374A4 (de) | 2007-12-05 | 2011-01-19 | Kyowa Hakko Kirin Co Ltd | Monoklonaler antikörper, der dazu fähig ist, sich an den heparinbindenden epidermalen-wachstumsfaktor-ähnlichen wachstumsfaktor zu binden |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| ES2530206T3 (es) | 2008-08-19 | 2015-02-27 | Cryovac, Inc. | Película adecuada para aplicaciones de envasado al vacío de tipo segunda piel y envase al vacío de tipo segunda piel fácil de abrir obtenido con la misma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK0573510T3 (da) * | 1991-01-17 | 1998-04-27 | Univ Washington | Antivækstfaktor antistoffer i behandlingen af vaskulær stenose |
| JP3708210B2 (ja) * | 1996-04-03 | 2005-10-19 | 協和醗酵工業株式会社 | 抗線維芽細胞増殖因子−８モノクローナル抗体 |
| JP4550947B2 (ja) * | 1997-03-19 | 2010-09-22 | 協和発酵キリン株式会社 | ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体 |
| JP2001046066A (ja) | 1999-08-03 | 2001-02-20 | Kyowa Hakko Kogyo Co Ltd | 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体 |
-
2002
- 2002-06-28 DE DE60226253T patent/DE60226253T2/de not_active Expired - Lifetime
- 2002-06-28 JP JP2003508988A patent/JP4152315B2/ja not_active Expired - Fee Related
- 2002-06-28 EP EP02743765A patent/EP1422243B1/de not_active Expired - Lifetime
- 2002-06-28 US US10/482,105 patent/US7939077B2/en not_active Expired - Fee Related
- 2002-06-28 CA CA002451854A patent/CA2451854A1/en not_active Abandoned
- 2002-06-28 AT AT02743765T patent/ATE393170T1/de not_active IP Right Cessation
- 2002-06-28 WO PCT/JP2002/006591 patent/WO2003002608A1/ja not_active Ceased
- 2002-06-28 AU AU2002346127A patent/AU2002346127B2/en not_active Ceased
- 2002-06-28 ES ES02743765T patent/ES2303859T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2451854A1 (en) | 2003-01-09 |
| EP1422243B1 (de) | 2008-04-23 |
| WO2003002608A1 (fr) | 2003-01-09 |
| DE60226253D1 (de) | 2008-06-05 |
| AU2002346127B2 (en) | 2008-05-29 |
| US7939077B2 (en) | 2011-05-10 |
| EP1422243A4 (de) | 2005-05-04 |
| JPWO2003002608A1 (ja) | 2004-10-14 |
| US20040253234A1 (en) | 2004-12-16 |
| JP4152315B2 (ja) | 2008-09-17 |
| EP1422243A1 (de) | 2004-05-26 |
| DE60226253T2 (de) | 2009-05-14 |
| ES2303859T3 (es) | 2008-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1078613A1 (zh) | 通过抗-erbb2抗体医治非恶性疾病或病患的疗法 | |
| ATE470676T1 (de) | Anti-vegf-2 antikörper | |
| MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
| MXPA02002384A (es) | Polipeptidos similares al factor de crecimiento de fibroblastos. | |
| BR0212756A (pt) | Molécula de anticorpo tendo especificidade para kdr humano, variante da molécula de anticorpo, composto, sequência de dna, vetor, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, e, uso da molécula de anticorpo | |
| ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
| DE60328747D1 (de) | Reinigung von polyreaktiven Autoantikörpern und deren Verwendungen | |
| ATE393170T1 (de) | Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers | |
| BR0308606A (pt) | Derivados de hemiasterlina e usos destes | |
| WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
| AU2003263712A1 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
| WO2004076614A3 (de) | Humane nukleinsäuresequenzen aus prostatakarzinomen | |
| AU2002326285A1 (en) | Method for treating psoriasis by using an il-17d antagonist | |
| WO2003048317A3 (en) | Antibodies to magmas and uses thereof | |
| WO2004030607A3 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
| BRPI0415355A (pt) | triarilimidazóis | |
| ITGE20020050A0 (it) | Procedimento per il trattamento di filati mediante agugliatura. | |
| WO2003037257A3 (en) | Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750 | |
| ATE328082T1 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
| DE60321443D1 (de) | Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung | |
| WO2002007740A3 (de) | Schlangentoxin und dessen verwendung als arzneimittel | |
| EP1566386A4 (de) | Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür | |
| NO20033401L (no) | Kjemiske forbindelser | |
| MXPA03010739A (es) | Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas. | |
| WO2001094530A3 (fr) | Nouveau polypeptide, proteine 57 de la sous-famille des proteines a doigt de zinc scan, et polynucleotide codant ce polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |